{"id":"adp-adoptive-cell-therapy","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"Adoptive cell therapy involves collecting, potentially modifying, and reinfusing a patient's own immune cells or donor cells to fight disease. The specific cell type, modification approach, and molecular targets for this ADP therapy have not been publicly characterized.","oneSentence":"Adoptive cell therapy that transfers immune cells to patients to enhance anti-tumor or anti-disease immune responses."},"_scrapedAt":"2026-03-28T05:50:32.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123449,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"tisagenlecleucel","brand":"Kymriah","company":"Novartis","rationale":"CAR-T cell therapy for hematologic malignancies"},{"name":"axicabtagene ciloleucel","brand":"Yescarta","company":"Gilead/Kite","rationale":"CAR-T cell therapy competing in adoptive cell therapy space"},{"name":"lifileucel","brand":"Amtagvi","company":"Iovance","rationale":"TIL-based adoptive cell therapy for solid tumors"}],"description":"ADP adoptive cell therapy is an investigational cellular immunotherapy being developed by USWM CT, LLC. Currently in Phase 1 clinical testing, this treatment involves the transfer of immune cells to patients, though specific molecular targets and therapeutic applications have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT03391778","phase":"PHASE1","title":"Adoptive Cell Therapy Long-term Follow-up (LTFU) Study","status":"RECRUITING","sponsor":"USWM CT, LLC","startDate":"2018-04-09","conditions":"Neoplasms","enrollment":250},{"nctId":"NCT06204991","phase":"PHASE1","title":"To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma","status":"RECRUITING","sponsor":"Inge Marie Svane","startDate":"2025-04-01","conditions":"Melanoma Stage III, Melanoma Stage IV, Melanoma","enrollment":10},{"nctId":"NCT06121557","phase":"PHASE1","title":"Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-01","conditions":"Breast Neoplasms","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ADP adoptive cell therapy","genericName":"ADP adoptive cell therapy","companyName":"USWM CT, LLC","companyId":"uswm-ct-llc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}